Model Medicines
US-based, artificial intelligence-driven drug discovery and development company
Based in CA
AI Overview
With $0 in lobbying spend across 10 quarterly filings, Model Medicines is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2023 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $0 |
| 2024 | $0 |
| 2025 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Model Medicines disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED, Health Issues, Pharmacy
Supporting Model Medicines as it seeks federal funding to further develop, receive FDA approvals for, and begin manufacturing for their drug, MDL-001, which has been identified as a potential best-in-
Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.